FDA Approves Tryptyr Eye Drops for Dry Eye Disease

Medically reviewed by Drugs.com.

By Stephanie Brown HealthDay Reporter

MONDAY, June 2, 2025 -- The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of signs and symptoms of dry eye disease.

Currently, dry eye disease treatment options are limited due to slow therapeutic onset, patient dissatisfaction, and poor adherence. Tryptyr works by stimulating corneal sensory nerves to rapidly increase natural tear production. The ophthalmic solution will be available in single-dose vials with a recommended dosage of one drop in each eye twice a day.

Approval of Tryptyr was based on the results of two phase 3 clinical trials (COMET-2 and COMET-3). More than 930 patients with a history of dry eye disease were randomly assigned (1:1) to Tryptyr or vehicle.

As early as day 1, Tryptyr delivered statistically significant natural tear production. Patients taking Tryptyr (versus vehicle) experienced a ≥10-mm increase in natural tear production at day 14 (42.6 versus 8.2 percent in COMET-2; 53.2 versus 14.4 percent in COMET-3). The results were consistent across all timepoints through day 90. The most common adverse reaction reported by patients in both studies was instillation site pain.

"Many of my patients continue to face frustrating challenges with dry eye management, and there is a clear need for additional treatment options," Marjan Farid, M.D., a professor of ophthalmology at the University of California, Irvine, said in a statement. “Tryptyr is the first eye drop that stimulates corneal nerves to directly address tear deficiency, a known cause of dry eye disease."

Approval of Tryptyr was granted to Alcon. Alcon anticipates launching Tryptyr in the United States during the third quarter of 2025.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords